RT Journal Article
T1 Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα-Induced Insulin Resistance.
A1 Lozano-Bartolome, Javier
A1 Llaurado, Gemma
A1 Portero-Otin, Manel
A1 Altuna-Coy, Antonio
A1 Rojo-Martinez, Gemma
A1 Vendrell, Joan
A1 Jorba, Rosa
A1 Rodriguez-Gallego, Esther
A1 Chacon, Matilde R
K1 Proto-Oncogene Proteins c-akt
K1 Signal Transduction
K1 Tumor Necrosis Factor-alpha
K1 Up-Regulation
AB The proinflammatory cytokine TNFα is a key player in insulin resistance (IR). The role of miRNAs in inflammation associated with IR is poorly understood. To investigate miR-181a-5p and miR-23a-3p expression profiles in obesity and to study their role in TNFα-induced IR in adipocytes. Two separate cohorts were used. Cohort 1 was used in adipose tissue (AT) expression studies and included 28 subjects with body mass index (BMI)  Expression of miR-181a-5p and miR-23a-3p was reduced in adipose tissue from obese and diabetic subjects and was inversely correlated to adiposity and homeostasis model assessment of IR index. Overexpression of miR-181a-5p and miR-23a-3p in adipocytes upregulated insulin-stimulated AKT activation and reduced TNFα-induced IR, regulating PTEN and S6K expression. Serum levels of miR-181a-5p were reduced in case vs control subjects at baseline, suggesting a prognostic value. Variable importance in projection scores revealed miR-181a-5p had more effect on the model than insulin or glucose at 120 minutes. miR-181a-5p and miR-23a-3p may prevent TNFα-induced IR in adipocytes through modulation of PTEN and S6K expression.
PB Oxford University Press
YR 2018
FD 2018-02-01
LK http://hdl.handle.net/10668/12089
UL http://hdl.handle.net/10668/12089
LA en
NO Lozano-Bartolomé J, Llauradó G, Portero-Otin M, Altuna-Coy A, Rojo-Martínez G, Vendrell J, et al. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα-Induced Insulin Resistance. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1447-1458
NO This study was supported by a project from the Fondo de Investigación Sanitaria (Grants PI14/00465 and PI17/00877 to M.R.C.), cofinanced by the European Regional Development Fund. M.R.C. is supported by the ResearchStabilization Program of the Instituto de Salud Carlos III cofinanced by Institut Catal`a de Salut in Catalonia.
DS RISalud
RD Apr 12, 2025